While PhIII Parkinson's trials go slower than expected, Cerevel previews plans to raise $900M
Tony Coles set out to build “the premier neuroscience company” at Cerevel. And that means putting fundraising plans in place well in advance.
Just weeks after tying the knot on a $599 million haul — from a dual stock sale and convertible debt arrangement — the biotech has filed a statement with the SEC to raise up to $900 million over the next few years.
“As part of good corporate housekeeping and in line with our goal to get new neuroscience medicines to people who need them as quickly as possible, we like to ensure that we have access to capital for the future; this filing is one of multiple tools we could use to do that; we made a similar filing last November as well,” a spokesperson told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
